Cyril Konto

physician researcher in immuno-oncology

[Cyril Konto @ckonto]

@Elisabeth_Borne Madame la Première Ministre, je me permets de vous interpeller au sujet des 30000 #valises en souffrance a #CDG. @GroupeADP, @AnneRigail et @airfrance ne nous donnent aucune information. Aidez-nous svp. https://t.co/pFyQmLZqSA

[Cyril Konto @ckonto]

Tomorrow at #IO360, I will be sharing preclinical data on Ichnos Sciences’ ISB 1442. I invite you to join the presentation, “Beyond the T cell: Co-targeting CD38 and CD47 with a 2+1 Biparatopic Multispecific Antibody”, at 12:20 pm.

[Cyril Konto @ckonto]

I’m honored to join Alessandro Riva and his team at #Ichnos Sciences as Chief Medical Officer and look forward to moving the IO pipeline and BEAT® platform ahead, including a new wave of trispecific immune cell engagers. https://t.co/z50vIcFqHU

[Cyril Konto @ckonto]

You’re a MD who is interested in a Clinical Lead position & excited to take on new challenges, join @allogenetx $ALLO https://t.co/27W16qsfEw

[Nasdaq Exchange @NasdaqExchange]

✨@AllogeneTx is pioneering the development of allogeneic CAR T therapies for cancer. Welcome to the Nasdaq family of the world’s most innovative companies! $ALLO

[Nasdaq Exchange @NasdaqExchange]

🔔Thank you for ringing the Opening Bell at @Nasdaq, @AllogeneTx. Congratulations on your IPO! $ALLO

[Cyril Konto @ckonto]

The Next Phase of Human Gene-Therapy Oversight | NEJM https://t.co/mz3Az34JgM

[Cyril Konto @ckonto]

Secreting PD-1-blocking scFv CAR-T cells improve anti-tumor activity of CAR-T & bystander tumor-specific T cells with paracrine/autocrine signaling in syngeneic and xenogeneic mouse models of PD-L1+ heme and solid tumors #MSKCC https://t.co/KNOiNbHBCP

[Allogene Therapeutics @AllogeneTx]

We are excited to announce the formation of our Scientific Advisory Board with leading oncology and immunology experts who will help guide our allogeneic cell therapy platform. https://t.co/qmTyWJHlFB

[Cyril Konto @ckonto]

Bravo! #FRAARG Congratulations to #ARG for fighting so hard!
#AllezLesBleus https://t.co/hdyPLk0MEZ

[EU Medicines Agency @EMA_News]

First two #CARTcell #medicines recommended for approval in the European Union https://t.co/QwCo5T4hhn #CHMP

[Bristol Myers Squibb @bmsnews]

What do @ericstonestreet, @dak and @TiaMowry have in common? They’ve all joined the #ReadyRaiseRise Pic Your Power challenge. Now it’s your turn!

[Latest News from Business Wire @NewsFromBW]

Pfizer and Allogene Therapeutics Enter into Asset Contribution Agreement for Pfizer’s Allogeneic CAR T Immuno-oncology Portfolio https://t.co/hcHvyVDagO

[Dr. Arie Belldegrun @Arie_Belldegrun]

Proud to be a part of the next revolution in CAR T therapy with forward-looking partners @AllogeneTx https://t.co/u6lSieqsP6

[Allogene Therapeutics @AllogeneTx]

Allogene is founded and led by former Kite executives who bring unrivaled clinical development acumen in cell therapy to accelerate the potential of allogeneic CAR T for patients. https://t.co/xThVLKgo92

[Cyril Konto @ckonto]

@France2tv bonjour pourquoi les JT ne sont ils plus disponibles en streaming des États Unis depuis le debut de Février?

[Nature Biotechnology @NatureBiotech]

A DNA #nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo https://t.co/PKa5ud1IOk

[Frédérique Vidal @VidalFrederique]

This morning, I am opening the 8th ARIIS and Aviesan International R&D Dating on the theme of Immuno-oncology. Let’s create together the conditions for better and more efficient therapies against cancer.

[Cyril Konto @ckonto]

Cancer immunotherapy in 2017: The breakthrough of the microbiota https://t.co/Liws8dhIcx